Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
Many small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development fo...
Main Authors: | Monica Giovannini, Vanesa Gregorc, Carmen Belli, Elisa Roca, Chiara Lazzari, Maria Grazia Viganò, Anna Serafico, Eugenio Villa |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2009-01-01
|
Series: | Journal of Oncology |
Online Access: | http://dx.doi.org/10.1155/2009/849051 |
Similar Items
-
PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review
by: Aurora Mirabile, et al.
Published: (2019-03-01) -
Genomic variations in the EGFR pathway in relation to skin toxicity of EGFR inhibitors analyzed by deep sequencing
by: Hasheminasab, Sayedmohammad
Published: (2015) -
Acneiform rash — skin toxic reaction to the use of EGFR inhibitors
by: E. A. Shatokhina, et al.
Published: (2019-01-01) -
Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
by: Angelo Corti, et al.
Published: (2010-01-01) -
Acute skin failure due to toxic epidermal necrolysis - Allopurinol induced
by: B S Gill, et al.
Published: (2016-01-01)